TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32649327

Group type: EXPERIMENTAL
Intervention: Cone-Beam CT (CBCT) imaging
Number of subjects: 87

Group type: COMPARATOR
Intervention: Electromagnetic Navigation (EMN)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CBCT with EMN
Number of subjects: 87

Group type: COMPARATOR
Intervention: EMN with CBCT
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Overall diagnostic accuracy per patient
Number of subjects: 87
Study: 35288545

Group type: EXPERIMENTAL
Intervention: Combinatorial pharmacogenomic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study: 33454714

Group type: EXPERIMENTAL
Intervention: Gyrus PlasmaKinetic system
Number of subjects: 113

Group type: COMPARATOR
Intervention: Olympus TURis system
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study: 36177501

Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil 2 hours before sexual relations twice a week
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil daily + 15 mg tadalafil 2 hours before sexual relations twice a week
Number of subjects: 60
Study: 33730421

Group type: EXPERIMENTAL
Intervention: Fully covered self‐expandable metal stents (FCSEMS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Multiple plastic stents (MPS)
Number of subjects: 30
Study: 32007823

Group type: EXPERIMENTAL
Intervention: Ramipril (ACEI)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitor beyond 1 year
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Increase in index of microcirculatory resistance from baseline to 1 year
Number of subjects: 91
Study: 33923235

Group type: EXPERIMENTAL
Intervention: 8% trehalose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8% glucose
Number of subjects: 12

Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 12
Study: 35905507

Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 32725573

Group type: EXPERIMENTAL
Intervention: Codeine phosphate associated with paracetamol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 47
Study: 32755802

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) targeting the ventral anterior limb of the internal capsule
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study: 35378408

Group type: EXPERIMENTAL
Intervention: Hand therapist
Number of subjects: 147

Group type: COMPARATOR
Intervention: Hand surgeons
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Three hand therapists
Number of subjects: 147
Study: 32335343

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 35690690

Group type: EXPERIMENTAL
Intervention: GHD before treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ISS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 33727208

Group type: EXPERIMENTAL
Intervention: Office hysteroscopy before IVF (Group I)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Immediate IVF (Group II)
Number of subjects: 171
Study: 36042674

Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 22

Group type: COMPARATOR
Intervention: Elective surgery
Number of subjects: 22
Study: 34656948

Group type: EXPERIMENTAL
Intervention: Developed anthropometric equation using calf circumference and other variables
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Developed anthropometric equation
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Previously reported equations
Number of subjects: 1262
Study: 35100279

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride (2%) injected intradermally using MicronJet600 device (MJ-Lido)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No injection (No pretreatment)
Number of subjects: 102
Study: 33032883

Group type: EXPERIMENTAL
Intervention: Steroid-free arm (Basiliximab + Tacrolimus + Azathioprine)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Steroid arm (Steroid + Tacrolimus + Azathioprine)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 104
Study: 32863109

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left temporoparietal area (LTA) and cathodal tDCS over the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo intervention (sham tDCS)
Number of subjects: 24
Study: 34133243

Group type: EXPERIMENTAL
Intervention: MOSAIC program (classroom intervention)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Typical practice control group
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: MOSAIC program (target children)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Typical practice control group (target children)
Number of subjects: 558
Study: 32672062

Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 34275239

Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang (JHWK) (14 days of quadruple therapy + 30 days of JHWK)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (14 days)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: All enrolled patients post-treatment
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Experimental group post-treatment
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Control group post-treatment
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 1054
Study: 32517785

Group type: EXPERIMENTAL
Intervention: Blood pressure self-management (daily home blood pressure monitoring and automated medication reduction via telemonitoring)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study: 35981565

Group type: EXPERIMENTAL
Intervention: Rivipansel
Number of subjects: 345
Study: 34116351

Group type: EXPERIMENTAL
Intervention: LPS challenge (1 replicate)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: LPS challenge (2 replicates)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: LPS challenge (0.4 mg/kg)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: LPS challenge (0.1, 0.2, and 0.8 mg/kg)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: LPS challenge (various dosages)
Number of subjects: 500
Study: 34409620

Group type: EXPERIMENTAL
Intervention: Nasal treatment using pure oxybuprocaine gel with adequate lubrication (group G)
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: 1% ephedrine in addition to oxybuprocaine gel with adequate lubrication (group EG)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Difficult advancement of the endotracheal tube
Number of subjects: 844
Study: 32513518

Group type: EXPERIMENTAL
Intervention: Combinatorial pharmacogenomic testing (guided-care)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 206
Study: 35766039

Group type: EXPERIMENTAL
Intervention: Continuous care combined with optimized insulin injection techniques
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (conventional continuous nursing)
Number of subjects: 96
Study: 34130395

Group type: EXPERIMENTAL
Intervention: Robenacoxib 2 mg/kg IM
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline IM (control)
Number of subjects: 12
Study: 35283454

Group type: EXPERIMENTAL
Intervention: Quadruple low calcineurin inhibitor (CNI) regimen
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard triple regimen
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Quadruple low CNI regimen
Number of subjects: 123
Study: 32241201

Group type: EXPERIMENTAL
Intervention: Procyanidins
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tannic acid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naringin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gallic acid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Glycyrrhizic acid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paeonol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 40
Study: 33878772

Group type: EXPERIMENTAL
Intervention: Caffeine treatment in the first 24 hours (group 1)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Caffeine treatment at the 72nd hour (group 2)
Number of subjects: 87
Study: 34992346

Group type: EXPERIMENTAL
Intervention: AD-206 (esomeprazole 20 mg or 40 mg + calcium carbonate 600 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional esomeprazole (Nexium®)
Number of subjects: 44
Study: 33080728

Group type: EXPERIMENTAL
Intervention: Uniportal VATS (UVATS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Multiportal VATS (MVATS)
Number of subjects: 69
Study: 35797000

Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill training
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Underwater walking therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 34454358

Group type: COMPARATOR
Intervention: Random synthetic transmit aperture (RSTA) method using a fraction of linear array elements in transmit mode.
Number of subjects: 0
Study: 35654466

Group type: EXPERIMENTAL
Intervention: Standard (reactive) induction therapy with ixazomib, lenalidomide, and dexamethasone (IRD)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Frailty-adjusted (adaptive) induction therapy with ixazomib, lenalidomide, and dexamethasone (IRD)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with lenalidomide+ixazomib
Number of subjects: 740

Group type: COMPARATOR
Intervention: Maintenance treatment with lenalidomide+placebo
Number of subjects: 740
Study: 34802955

Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation (KK)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Classical music listening (ML)
Number of subjects: 25
Study: 32845740

Group type: EXPERIMENTAL
Intervention: 120 mg galcanezumab (240 mg loading dose)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 240 mg galcanezumab
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: galcanezumab
Number of subjects: 106

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 106
Study: 33899528

Group type: EXPERIMENTAL
Intervention: Free thyroxine (fT4) levels
Number of subjects: 170756

Group type: EXPERIMENTAL
Intervention: Thyrotropin (TSH) levels
Number of subjects: 170756

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to MDD and BD
Number of subjects: 170756
Study: 32597373

Group type: EXPERIMENTAL
Intervention: Challenge condition (n=40) received daily emails for 24 days highlighting a particular strength, its value, implementation strategies, and a motto.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control condition (n=35) received daily emails containing only the motto for each strength for 24 days.
Number of subjects: 75
Study: 33607813

Group type: EXPERIMENTAL
Intervention: Ketorolac plus Lidocaine (30 mg Ketorolac and 2% Lidocaine - adrenaline)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Lidocaine (2% Lidocaine - adrenaline)
Number of subjects: 128
Study: 33090904

Group type: EXPERIMENTAL
Intervention: Exposure to biological dust
Number of subjects: 17833

Group type: EXPERIMENTAL
Intervention: Exposure to mineral dust
Number of subjects: 17833

Group type: EXPERIMENTAL
Intervention: Exposure to metals
Number of subjects: 17833
Study: 34267122

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Comparison of cleft lip alone vs cleft lip and palate
Number of subjects: 28
Study: 34024693

Group type: EXPERIMENTAL
Intervention: Dermabond Prineo
Number of subjects: 51

Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 51
Study: 32102033

Group type: EXPERIMENTAL
Intervention: Extended subscleral tunnel (ESST)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional subscleral trabeculectomy (SST)
Number of subjects: 40
Study: 34873023

Group type: EXPERIMENTAL
Intervention: PENG group (20 mL 0.5% ropivacaine)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo group (20 mL saline)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PENG group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 71
Study: 32619415

Group type: EXPERIMENTAL
Intervention: Self-expanding intra-annular transcatheter heart valves
Number of subjects: 180

Group type: COMPARATOR
Intervention: Commercially available transcatheter heart valves
Number of subjects: 180
Study: 33806822

Group type: EXPERIMENTAL
Intervention: FACR diet (five days’ carbohydrate < 20% and fat > 60% energy, plus one‐day carbohydrate ≥ 70% energy)
Number of subjects: 8

Group type: COMPARATOR
Intervention: HCHO diet (carbohydrate > 60% energy; fat < 20% energy)
Number of subjects: 8
Study: 32603996

Group type: EXPERIMENTAL
Intervention: 30 min of moderate-intensity exercise on a cycling ergometer (n = 37)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Seated rest (n = 47)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 30 min of moderate-intensity exercise
Number of subjects: 84

Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 84
Study: 33301926

Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty (rTSA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty (rTSA) in patients aged ≥ 80 years
Number of subjects: 99

Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA) in patients aged ≥ 80 years
Number of subjects: 99
Study: 32094159

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 0
Study: 35711147

Group type: EXPERIMENTAL
Intervention: Test formulation (3 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Test formulation (4 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Test formulation (6 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reference voriconazole (3 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reference voriconazole (4 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reference voriconazole (6 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 34153141

Group type: EXPERIMENTAL
Intervention: C-MAC Miller videolaryngoscope
Number of subjects: 140

Group type: COMPARATOR
Intervention: McGrath MAC size-1 videolaryngoscope
Number of subjects: 140
Study: 32574009

Group type: EXPERIMENTAL
Intervention: Retinol serum (0.25%, 0.5%, 1.0%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tretinoin cream (0.025%, 0.05%, 0.1%)
Number of subjects: 45
Study: 35684089

Group type: EXPERIMENTAL
Intervention: Whey protein (25 g) and Vitamin D3 (4000 IU) before bedtime
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Whey protein (25 g) and Vitamin D3 (4000 IU) after sleeping
Number of subjects: 42

Group type: COMPARATOR
Intervention: Maltodextrin placebo (5 g) - Control group
Number of subjects: 42
Study: 34639501

Group type: EXPERIMENTAL
Intervention: BJ-400
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BJ-800
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 8
Study: 35107694

Group type: EXPERIMENTAL
Intervention: KEEP-P (core PMT Oregon Model methods)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: KEEP-V (integrated KEEP with Filming Interactions to Nurture Development video coaching)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Higher intervention dosage
Number of subjects: 175
Study: 33412281

Group type: EXPERIMENTAL
Intervention: 10 Hz AM-tACS targeting the visual cortex
Number of subjects: 7

Group type: COMPARATOR
Intervention: No artifact rejection method applied
Number of subjects: 7
Study: 35318229

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Combination of Methotrexate and Adalimumab
Number of subjects: 192
Study: 32178640

Group type: EXPERIMENTAL
Intervention: Therapist guided internet-delivered cognitive therapy (TG-iConquerFear)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Augmented treatment as usual (aTAU)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: TG-iConquerFear
Number of subjects: 246
Study: 35805372

Group type: COMPARATOR
Intervention: GS + CST
Number of subjects: 362

Group type: COMPARATOR
Intervention: CST
Number of subjects: 362

Group type: COMPARATOR
Intervention: GS
Number of subjects: 362
Study: 33276704

Group type: COMPARATOR
Intervention: LT4/LT3 combination therapy
Number of subjects: 0
Study: 35126618

Group type: EXPERIMENTAL
Intervention: nano‐Pueraria targeted preparation + Tuina therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tuina therapy
Number of subjects: 200
Study: 34296979

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 32052217

Group type: EXPERIMENTAL
Intervention: 1,000 IU/day of vitamin D3 supplementation
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 2,000 IU/day of vitamin D3 supplementation
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 4,000 IU/day of vitamin D3 supplementation
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 35153118

Group type: EXPERIMENTAL
Intervention: Cold water spray (0.4 mL per application, twice every hour)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cold saline spray (0.4 mL per application, twice every hour)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (water at room temperature, 1-2 mL using a syringe)
Number of subjects: 104
Study: 32898082

Group type: EXPERIMENTAL
Intervention: Topical vancomycin powder at wound closure
Number of subjects: 583
Study: 33094385

Group type: EXPERIMENTAL
Intervention: Cold/dry, cold/humid, warm/dry, warm/humid settings
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sniffin’ Sticks test battery
Number of subjects: 50
Study: 32597616

Group type: EXPERIMENTAL
Intervention: RI-3 (3 min rest interval)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RI-1 (1 min rest interval)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RI-2 (2 min rest interval)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RI-1, RI-2, RI-3
Number of subjects: 20
Study: 34153729

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (MP) 40 mg twice daily for 7 days
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (MP) plus tocilizumab (400 mg single dose)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care (historical control)
Number of subjects: 76
Study: 32629706

Group type: EXPERIMENTAL
Intervention: Nurse-led hypertension management model for 12 weeks
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study: 35124256

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa isolates
Number of subjects: 23
Study: 33566105

Group type: EXPERIMENTAL
Intervention: Personalized weekly coupons with nutrition education during the intervention period (A)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Occasional generic coupons with nutrition education during the control period (B)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Personalized weekly coupons with nutrition education during the crossover intervention period (A)
Number of subjects: 224
Study: 32461420

Group type: EXPERIMENTAL
Intervention: 0.5% CMC + 2000 IU vitamin D through buccal spray (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5% CMC + 2000 IU vitamin D through buccal spray + 0.05% cyclosporine (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.5% CMC (Group A)
Number of subjects: 90
Study: 35297973

Group type: EXPERIMENTAL
Intervention: Default order for HCV screening implemented within the admission order set (hospital B during wedge 2)
Number of subjects: 7634

Group type: COMPARATOR
Intervention: Default order for HCV screening implemented within the admission order set (hospital A during wedge 3)
Number of subjects: 7634

Group type: COMPARATOR
Intervention: Electronic alert prompting clinicians to consider HCV screening (wedge 1)
Number of subjects: 7634
Study: 36368748

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavioural therapy in a group setting (CA-CBT+)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 138
Study: 34507009

Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA)
Number of subjects: 248
Study: 36355434

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 33337365

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35021204

Group type: EXPERIMENTAL
Intervention: Bonded multistranded PentaOne (Masel Orthodontics) retainer 13-23
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bonded multistranded PentaOne (Masel Orthodontics) retainer 12-22
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Removable vacuum-formed retainer (VFR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: All three retention methods
Number of subjects: 90
Study: 32076819

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 international units, intranasal application)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 34431029

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with antidepressants for 3 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Antidepressants monotherapy for 3 weeks
Number of subjects: 70
Study: 32662184

Group type: EXPERIMENTAL
Intervention: Training program (multicomponent community-based training program)
Number of subjects: 142
Study: 34478430

Group type: EXPERIMENTAL
Intervention: Virtual reality (n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: E-learning (n = 9)
Number of subjects: 20